Efficacy of mesalazine in the treatment of symptomatic diverticular disease

Francesco Di Mario, Giovanni Aragona, Gioacchino Leandro, Giuseppe Comparato, Libera Fanigliulo, Lucas G. Cavallaro, Giulia M. Cavestro, Veronica Iori, Marta Maino, Alì M. Moussa, Alessandro Gnocchi, Giancarlo Mazzocchi, Angelo Franzé

Research output: Contribution to journalArticlepeer-review


We aimed to improve symptoms by means of mesalazine in symptomatic colonic diverticular disease patients. One hundred seventy outpatients (98 M, 72 F; age, 67.1 years; range, 39-84 years) were assigned to four different schedules: rifaximin, 200 mg bid (Group R1: 39 pts), rifaximin, 400 mg bid (Group R2: 43 pts), mesalazine, 400 mg bid (Group M1: 40 pts), and mesalazine, 800 mg bid (Group M2: 48 pts), for 10 days per month. At baseline and after 3 months we recorded 11 clinical variables (upper/lower abdominal pain/discomfort, bloating, tenesmus, diarrhea, abdominal tenderness, fever, general illness, nausea, emesis, dysuria), scored from 0 = no symptoms to 3 = severe. The global symptomatic score was the sum of all symptom scores. After 3 months in all schedules but Group R1, 3 of the 11 symptoms improved (P <0.03); the global score decreased in all groups but Group R1 (P <0.0001). Mesalazine-treated patients had the lowest global score at 3 months (P <0.001). Mesalazine is as effective as rifaximin (higher dosage schedule) for diminishing some symptoms, but it appears to be better than rifaximin for improving the global score in those patients.

Original languageEnglish
Pages (from-to)581-586
Number of pages6
JournalDigestive Diseases and Sciences
Issue number3
Publication statusPublished - Mar 2005


  • Diverticula
  • Diverticular disease
  • Mesalazine
  • Rifaximin

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Efficacy of mesalazine in the treatment of symptomatic diverticular disease'. Together they form a unique fingerprint.

Cite this